Cantor Fitzgerald Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to “Overweight”

Cantor Fitzgerald upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a neutral rating to an overweight rating in a research report report published on Thursday morning, Marketbeat reports. They currently have $167.00 price objective on the biotechnology company’s stock, up from their previous price objective of $152.00.

Several other research analysts also recently commented on the stock. Citigroup cut their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their price objective for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James reiterated an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, UBS Group boosted their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Buy” and an average target price of $181.33.

Sarepta Therapeutics Trading Up 1.0 %

Shares of Sarepta Therapeutics stock opened at $121.61 on Thursday. The company’s 50-day moving average price is $125.92 and its 200-day moving average price is $132.97. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a 12-month low of $75.85 and a 12-month high of $173.25. The company has a market cap of $11.60 billion, a price-to-earnings ratio of 97.29 and a beta of 0.81.

Insider Activity at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Sarepta Therapeutics by 30.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock valued at $9,772,000 after buying an additional 18,095 shares during the period. Commerce Bank lifted its stake in Sarepta Therapeutics by 15.7% in the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock worth $252,000 after acquiring an additional 274 shares during the period. Braun Stacey Associates Inc. boosted its holdings in Sarepta Therapeutics by 4.9% in the third quarter. Braun Stacey Associates Inc. now owns 103,012 shares of the biotechnology company’s stock valued at $12,865,000 after acquiring an additional 4,827 shares in the last quarter. AM Squared Ltd increased its position in Sarepta Therapeutics by 600.0% during the 3rd quarter. AM Squared Ltd now owns 1,400 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 1,200 shares during the period. Finally, Mizuho Markets Americas LLC raised its holdings in Sarepta Therapeutics by 22.3% in the 3rd quarter. Mizuho Markets Americas LLC now owns 399,065 shares of the biotechnology company’s stock worth $49,839,000 after purchasing an additional 72,765 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.